Baicalein

Recombinant mouse IL-1β was obtained from R&D Systems (Minneapolis, MN, USA). MCC950 (NLRP3 inhibitor, cat no. inh-mcc) was obtained from Invitrogen (San Diego, CA, USA). Lipopolysaccharide (LPS, Escherichia coli serotype O55:B5), dexamethasone (cat no. D4902), and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). MK886 (5-LOX inhibitor, cat no. 475889) was obtained from Calbiochem (La Jolla, CA, USA). Ac-YVAD-cmk (caspase-1 inhibitor, cat no. ALX-260-028), U75302 (BLT1 antagonist, BML-RA102-0100) and baicalein (12-LOX inhibitor, BML-EI106-0050) were obtained from Enzo Life Sciences (Farmingdale, NY, USA). LY255283 (BLT2 antagonist, cat no. 70715) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Antibodies against NLRP3 and caspase-1 were purchased from AdipoGen Life Sciences (San Diego, CA, USA).

LPS (Escherichia coli serotype O55:B5) and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (St Louis, MO). The BLT1 antagonist U75302 and the 12-LO inhibitor Baicalein were obtained from Enzo Life Sciences (Farmingdale, NY). The BLT2 antagonist LY255283 was obtained from Cayman Chemical (Ann Arbor, MI). The 5-LO inhibitor MK886 and the NF-κB inhibitor Bay11-7082 were obtained from Calbiochem (La Jolla, CA).

Dexamethasone, dimethyl sulfoxide (DMSO), LPS (Escherichia coli serotype O55:B5), and ovalbumin were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 12-LO inhibitor baicalein and BLT2 antagonist LY255283 were purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA) and Cayman Chemical (Ann Arbor, MI, USA), respectively. Antibodies against BLT2, 12-LO, and GAPDH were obtained from Enzo Life Sciences, Inc., Invitrogen (Rockford, IL, USA), and Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), respectively. Neutralizing monoclonal antibodies against G-CSF and the IgG1 isotype control were obtained from R&D Systems (Minneapolis, MN, USA).